Telomir-1 inhibits KDM5 demethylase families in vitro, expanding epigenetic targeting

Telomir Pharmaceuticals, Inc.

Telomir-1 inhibits KDM5A, KDM5B, and KDM5C in vitro, blocking silencing of tumor suppressor genes.
Adds to prior activity on KDM2/KDM6 families and DNA methylation, unique among epigenetic therapies.
Telomir-1 spared GCN5L2 acetyltransferase, indicating potential for reduced systemic toxicity.
IND-enabling studies and GMP scale-up ongoing; additional preclinical evaluations in cancer and aging.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.